Find Effective Drugs before Starting the Therapy!

No two cancer therapies are the same!

There is a wide range of different drugs which can be applied in treatment of non-small-cell lung cancer. This treatment includes classical chemotherapeutic substances, yet also new targeted drugs are used. Which medication should be prescribed depends on different factors, e.g. the cancer stage and the general condition of the patient. In order to choose the right therapy there are medical guidelines for physicians. However, in some situations the guidelines do not give clear recommendations and propose equivalent treatment options.

Diagnostic assays can help to identify effective and ineffective drugs before the start of a therapy. The available spectrum of therapeutics can thereby be limited on the most promising substances. Our diagnostics contribute avoidance of unnecessary side effects as a consequence of an ineffective therapy and save valuable treatment time. Therefore we offer the following diagnostic tests:

 

  • CTR-Test® - An efficacy test working on living tumor cells

  • PCDx™ - A tumor-biomarker-analysis working on non-living, conserved tumor cells

  • Guardant360® - A tumor-biomarker-analysis working with blood


Guidelines for the Treatment of Non-Small-Cell Lung Cancer

Hereafter you can find an overview about guideline-recommendations, which are elaborated by medical specialist associations:

There are two different types of lung cancer to be distinguished: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer. It is classified into four stages and therapy recommendations vary accordingly. For stages I to III, therapy aims at curing cancer. In contrast, improving quality of life through palliative care is the primary goal for patients with stage IV cancers (generally involve multiple metastases). A stage IV classification makes testing of certain genetic markers necessary: An ALK/ROS1 translocation (two proto-oncogenes) and/or a mutation of EGRF (a growth factor receptor) will have an impact on treatment.

Stage I (curative) after operation no further chemotherapy
Stage II (curative) cisplatin + vinorelbine
cisplatin + docetaxel
cisplatin + gemcitabine
cisplatin + pemetrexed
cisplatin + paclitaxel
Stage III (curative) cisplatin + vinorelbine
cisplatin + docetaxel
cisplatin + gemcitabine
cisplatin + pemetrexed
cisplatin + paclitaxel
cisplatin + etoposide
cisplatin
carboplatin
Stage IV (palliative) test for translocation of ALK/ROS1 and mutation of EGFR. The further therapy depends on the results. platinum-based therapy +/- bevacizumab
platinum derivatives + cytostatic agent of the 3rd generation (e.g. gemcitabine, pemetrexed, taxanes, vinorelbine)
crizotinib
ceritinib
afatinib or other EGFR-tyrosine-kinase-inhibitors
docetaxel +/- nintedanib
pemetrexed
erlotinib
nivolumab

This table is based on the "Leitlinie Lungenkarzinom, nicht-kleinzellig (NSCLC)", issued by the German Society for Haematology and Medical Oncology (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., DGHO), published on onkopedia.de [1].


Efficacy Tests of Drugs for Non-Small-Cell Lung Cancer

Which drugs can be tested in their efficacy by our diagnostic tests? The following tables give you information on the substances recommended by the guidelines, but also about further drugs which can be found as additional treatment options in literature. These substances are classified in the following categories:

In addition the frequently used combination therapies are listed below.

The testabilities for the CTR-Test®  and the PCDx™ are also given.

Chemotherapeutics

substance name

efficacy testable by

CTR-Test Logo

efficacy testable by

PCDx Logo

efficacy testable by

Guardant360 Logo

Referenz
carboplatin yes yes yes [2]
cisplatin yes yes yes [1], [2], [3]
docetaxel yes yes not yet [1], [2], [3]
gemcitabine yes yes not yet [1], [2], [3]
paclitaxel yes yes not yet [1], [2], [3]
pemetrexed no yes not yet [1], [2], [3]
vinorelbine yes yes not yet [1], [2]
 

Targeted Drugs

substance name

efficacy testable by

CTR-Test Logo

efficacy testable by

PCDx Logo

efficacy testable by

Guardant360 Logo

Referenz
afatinib no validation yet yes yes [1], [3]
bevacizumab no yes not yet [1]
ceritinib no validation yet yes yes [1], [3]
cetuximab no validation yet yes yes [3]
crizotinib no validation yet yes yes [1], [2], [3]
dabrafenib no validation yet yes yes [3]
erlotinib no validation yet yes yes [1], [2], [3]
gefitinib no validation yet yes yes [2], [3]
nintedanib no no biomarkers yet not yet [1]
nivolumab no validation yet yes not yet [1], [3]
trastuzumab no validation yet yes yes [3]
vemurafenib no validation yet yes yes [3]

 

Frequently Used Combination Therapies

substance name reference
carboplatin + docetaxel [1]
carboplatin + gemcitabine [1], [2]
carboplatin + paclitaxel [1], [2]
carboplatin + pemetrexed [1], [2]
carboplatin + vinorelbine [1], [2]
cisplatin + docetaxel [1]
cisplatin + etoposide [1]
cisplatin + gemcitabine [1], [2], [3]
cisplatin + paclitaxel [1]
cisplatin + pemetrexed [1], [2]
cisplatin + vinorelbine [1], [2]
docetaxel + nintedanib [1]
combination therapy containing platinum + bevacizumab [1]

The drugs listed here were identified as potential therapy options after an accurate literature research. Completeness cannot be guaranteed. Status: September 2016.


Just call us:

Monday to Thursday from 9:00 - 16:00
and Friday from 9:00 - 15:00

Our phone number:
+49 6221-8936-157

Send us a message:

We will get back to you as soon as possible.
Your TherapySelect Team


Our Awards

Award for innovative research
Award from the Federal Ministry of Education and Research, Germany
Award from the Federal Ministry for Economic Affairs and Energy of Germany
Award from the European Union